Durable treatment response of relapsing CNS plasmacytoma using intrathecal chemotherapy, radiotherapy, and Daratumumab. Issue 4 (2nd March 2018)

• Record Type: Journal Article
• Authors: Elhassadi, Ezzat; Murphy, Maurice; Hacking, Dayle; Farrell, Michael
• Is Part Of: Clinical case reports. Volume 6:Issue 4(2018)
• Page Start: 723
• Page End: 728
• Publication Date: 2018-03-02
• Subjects: CNS plasmacytoma -- Daratumumab -- extramedullary myeloma -- intrathecal chemotherapy -- radiotherapy; Medicine -- Periodicals; 616.09
• DOI: 10.1002/ccr3.1451
• Languages: English
• ISSNs: 2050-0904

Abstract

Key Clinical Message: CNS myelomatous involvement is a rare complication of multiple myeloma with dismal outcome. This disease's optimal treatment is unclear. Combined approach of systemic therapy, radiotherapy, and intrathecal injections chemotherapy should be considered and autologous stem cell transplant consolidation is offered to eligible patients. The role of Daratumumab in this disease deserves further evaluation. Abstract : CNS myelomatous involvement is a rare complication of multiple myeloma with dismal outcome. This disease's optimal treatment is unclear. Combined approach of systemic therapy, radiotherapy, and intrathecal injections chemotherapy should be considered and autologous stem cell transplant consolidation is offered to eligible patients. The role of daratumumab in this disease deserves further evaluation.